mocertatug rezetecan

News

GSK's B7-H4-targeting ADC Mo-Rez chalks up impressive results in ovarian and endometrial cancer, prompting a major phase 3 trials programme.

News

An AI tool could identify colorectal cancer patients most likely to respond to bevacizumab, which was recently backed for NHS use.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.